Kim Merritt

Cooley advised the initial purchasers on Ascendis Pharma’s offering of $575 million aggregate principal amount of 2.25% Convertible Senior Notes due 2028 and the concurrent repurchase of 1,000,000 of its American Depositary Shares. J.P. Morgan, Evercore ISI, Wells Fargo Securities, Morgan Stanley and Credit Suisse acted as joint book-running managers for the offering. SVB Leerink acted as lead co-manager for the offering. Cantor, Canaccord Genuity and Berenberg acted as co-managers for the offering.  Ascendis Pharma is a biopharmaceutical company creating new product candidates that address unmet medical needs. Partners Denny Won, Mischi a Marcha, Jason Savich, Charlie Kim and Div Gupta led the Cooley team advising the initial purchasers.

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.

Cooley advised the underwriters on Erasca’s $345 million initial public offering of 21,562,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Erasca, whose securities now trade on the Nasdaq Global Select Market under the symbol ERAS, is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.

Cooley advised digital health automation company Olive on its $400 million funding round, which brings its valuation to $4 billion. Lawyers Peter Werner and Melissa Boyd led the Cooley team advising Olive.

Cooley advised NVIDIA on its registered debt offering of $5 billion aggregate principal amount of investment grade senior unsecured notes. The offering consisted of $1.25 billion aggregate principal amount of 0.309% notes due 2023; $1.25 billion aggregate principal amount of 0.584% notes due 2024; $1.25 billion aggregate principal amount of 1.550% notes due 2028; and $1.25 billion aggregate principal amount of 2.000% notes due 2031. Partners Michael Tollini, Mischi a Marca, Jason Savich, Eric Jensen and John McKenna led the Cooley team advising NVIDIA.